Question:

Which of the following newer drugs has activity on both HER1 and HER2 receptors?

Show Hint

Used in HER2-positive breast cancer and also hits EGFR: think dual inhibitor.
Updated On: Jun 24, 2026
  • Erlotinib
  • Gefitinib
  • Canertinib
  • Lapatinib
Show Solution
collegedunia
Verified By Collegedunia

The Correct Option is D

Solution and Explanation

Step 1: HER1 is the same as EGFR, and HER2 is the same as ErbB2/neu. The question asks for a single drug that inhibits the tyrosine kinase of both receptors.

Step 2: Lapatinib is a dual tyrosine kinase inhibitor that blocks both HER1 (EGFR) and HER2. It is used in HER2-positive breast cancer, often with capecitabine. So option D is correct.

Step 3: Erlotinib (A) and gefitinib (B) are selective inhibitors of HER1 (EGFR) only and are used mainly in non-small-cell lung cancer. They do not target HER2. So A and B are wrong.

Step 4: Canertinib (C) is an irreversible pan-ErbB inhibitor that was investigational and never reached routine clinical use. Among the listed approved drugs, lapatinib is the established dual HER1/HER2 agent intended by this question. So C is not the intended answer.

Conclusion: The drug with activity on both HER1 and HER2 is lapatinib, option D.
Was this answer helpful?
0
0